Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.

Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.

Publication date: Jan 01, 2025

Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes. This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna’s mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (

Concepts Keywords
Computer 2019-nCoV Vaccine mRNA-1273
Mrna 2019-nCoV Vaccine mRNA-1273
Naive Adult
Vaccine Aged
Antibodies, Monoclonal
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antibodies, Neutralizing
Antibodies, Viral
Antibodies, Viral
casirivimab
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Humans
imdevimab
Male
Middle Aged
Prospective Studies
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease IDO protein

Original Article

(Visited 2 times, 1 visits today)